Edition:
United States

Intellipharmaceutics International Inc (IPCI.OQ)

IPCI.OQ on NASDAQ Stock Exchange Capital Market

1.91USD
1:56pm EDT
Change (% chg)

$-0.05 (-2.55%)
Prev Close
$1.96
Open
$1.99
Day's High
$1.99
Day's Low
$1.86
Volume
32,612
Avg. Vol
39,444
52-wk High
$3.34
52-wk Low
$1.41

Latest Key Developments (Source: Significant Developments)

Intellipharmaceutics Q1 loss per share $0.07
Tuesday, 11 Apr 2017 09:24pm EDT 

Intellipharmaceutics International Inc : Intellipharmaceutics announces first quarter 2017 results . Q1 loss per share $0.07 .Q1 revenue $1.2 million versus $600,000.  Full Article

Intellipharmaceutics Q1 loss per share $0.07
Tuesday, 11 Apr 2017 06:48pm EDT 

Intellipharmaceutics International Inc : Intellipharmaceutics announces first quarter 2017 results . Q1 loss per share $0.07 .Q1 revenue $1.2 million versus $600,000.  Full Article

Intellipharmaceutics announces patent litigation by Purdue against its Rexista abuse-deterrent extended-release Oxycodone
Monday, 10 Apr 2017 08:00am EDT 

Intellipharmaceutics International Inc : Intellipharmaceutics announces patent litigation by purdue against its Rexista™ abuse-deterrent extended-release Oxycodone .Intellipharmaceutics International - on April 7, Purdue, plaintiffs alleged that Rexista infringes six (6) out of sixteen (16) patents.  Full Article

Intellipharmaceutics announces FDA approval for 500 mg and 750 mg generic Glucophage XR
Friday, 24 Feb 2017 08:00am EST 

Intellipharmaceutics International Inc : Intellipharmaceutics announces FDA approval for 500 mg and 750 mg generic Glucophage® XR .Intellipharmaceutics International Inc - actively evaluating options to realize commercial returns from new approval.  Full Article

IntellipPharmaceutics announces 2016 year end results
Friday, 10 Feb 2017 08:00am EST 

Intellipharmaceutics International Inc - : IntelliParmaceutics announces 2016 year end results . Currently expect to satisfy our operating cash requirements until Jne 2017 from cash on hand . Expect to utilize at-market offering program to bridge any funding shortfall in first and second quarters of 2017 .In second half of fiscal 2017, company expects revenues to improve.  Full Article

IntelliPharmaCeutics announces FDA acceptance for filing of marketing application for Rexista
Thursday, 2 Feb 2017 05:00pm EST 

IntelliPharmaCeutics International Inc : IntelliPharmaCeutics announces FDA acceptance for filing of NDA for Rexista™ (oxycodone hydrochloride extended release), an abuse deterrent opioid analgesic for the treatment of moderate to severe pain . IntelliPharmaCeutics International Inc - FDA set a target action date under prescription drug user fee act ("PDUFA") of September 25, 2017 .IntelliPharmaCeutics International Inc - FDA has determined that company's application is sufficiently complete to permit a substantive review.  Full Article

Intellipharmaceutics announces issuance of U.S. and Canadian patents covering Podras overdose technology
Wednesday, 21 Dec 2016 08:00am EST 

Intellipharmaceutics International Inc :Intellipharmaceutics announces issuance of U.S. and Canadian patents covering aspects of its Podras overdose technology.  Full Article

Intellipharmaceutics submits new drug application for Rexista
Friday, 25 Nov 2016 07:45am EST 

Intellipharmaceutics International Inc : Intellipharmaceutics submits new drug application for Rexista® (oxycodone hydrochloride extended release), an abuse deterrent opioid analgesic for the treatment of moderate to severe pain .Intellipharmaceutics International - Has identified potential manufacturing partners; currently evaluating manufacturing options for Rexista in U.S..  Full Article

Intellipharmaceutics signs an exclusive license deal with Mallinckrodt
Tuesday, 11 Oct 2016 04:46pm EDT 

Intellipharmaceutics International Inc : Intellipharmaceutics signs an exclusive license and commercial supply agreement with mallinckrodt . Intellipharmaceutics international inc - Intellipharmaceutics will receive a non-refundable upfront payment of US$3 million in October 2016 . Intellipharmaceutics International Inc - has agreed to manufacture and supply licensed products exclusively for mallinckrodt . Intellipharmaceutics international inc - Mallinckrodt has agreed that Intellipharmaceutics will be its sole supplier of licensed products marketed in u.s .Intellipharmaceutics International- agreement provides for company to have long-term profit sharing arrangement with respect to licensed products.  Full Article

Intellipharmaceutics announces FDA tentative approval for generic Seroquel XR
Friday, 7 Oct 2016 06:35pm EDT 

Intellipharmaceutics International Inc : Says received tentative approval from u.s. Fda for co's new drug application for quetiapine fumarate . Launch of its generic versions of seroquel xr is subject to fda final approval of co's anda . Intellipharmaceutics announces fda tentative approval for generic seroquel xr® . Intellipharmaceutics announces fda tentative approval for generic seroquel xr® .Pursuant to settlement between co & astrazeneca in 2012, co is permitted to launch generic versions of seroquel xr on nov 1 2016.  Full Article

More From Around the Web

BRIEF-Intellipharmaceutics Q1 loss per share $0.07

* Q1 revenue $1.2 million versus $600,000 Source text for Eikon: Further company coverage: